Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Efficacy, and PK of QL-007 in Chronic Hepatitis B
NCT03770624Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of QL-007 in Chronic Hepatitis B (CHB) (6 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Change in serum HBV DNA from baseline at Day 28. Status: unknown.
02
Drugs
QL-007
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03770624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770624.